ALSO NOTED: Teva loses out on Celebrex copycat; Wyeth to build $280M plant in China;

> Switzerland's Cytos stirred up some excitement with its announcement that new trial data backs up its hopes for a new vaccine that can be used to thwart high blood pressure. Report

> A federal appeals court tossed out one of Pfizer's three patents on the painkiller Celebrex, but upheld a lower court's decision that ruled out a copycat version from Teva Pharmaceutical Industries because it would infringe on the remaining two. The ruling would keep Teva's generic off the market till 2015. Report | Report

> Wyeth plans to spend $280 million to build a plant in China that will make mostly infant formula and nutritional products for the regional market; when complete in 2010, it's expected to employ 300. Release

> Immunicon plans to cut 45 of its 100 workers after a dispute over the marketing of its CellSearch cancer test with Veridex, a Johnson & Johnson unit. Report

> Eleven drug makers have agreed to pay $125 million over average wholesale prices after a lawsuit charged that consumers and payors paid more than they should have because of false reporting. The new settlement includes Abbot, Amgen, Sanofi-Aventis, Baxter, Bayer, and others. Report

> The FDA gave its nod for Spectrum Pharmaceuticals' oncology drug Levoleucovorin; the company expects to launch by June. Report

> Cepheid is cashing in on MRSA trends--for now. Report

And Finally... Who keeps drug-sample inventories and rides herd on departing sales reps? Sports trainers. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.